Histone deacetylase inhibitors: a novel class of therapeutic agents in diabetic nephropathy.
Histone deacetylase (HDAC) inhibitors are currently being tested as anticancer agents in clinical trials. Chromatin remodeling, such as through histone acetylation, is a fundamental phenomenon in eukaryotic cell biology, bearing implications to numerous physiological and pathological phenomena. Here, we discuss recent data from our own laboratory and those of others demonstrating antifibrotic and renoprotective effect of HDAC inhibitors in diabetic kidneys, and the possible mechanisms including the role of reactive oxygen species. HDAC inhibitors may prove to be a novel class of multitarget agents in the treatment of diabetic nephropathy.
Lee
H B
HB
Hyonam Kidney Laboratory, Soon Chun Hyang University, Seoul, Korea.
Noh
H
H
Seo
J Y
JY
Yu
M R
MR
Ha
H
H
D000107:Acetylation; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003928:Diabetic Nephropathies / Q000188:drug therapy / Q000517:prevention & control*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D056572:Histone Deacetylase Inhibitors; D006655:Histone Deacetylases / Q000502:physiology; D006657:Histones / Q000378:metabolism; D006801:Humans; D007527:Isoenzymes / Q000502:physiology; D051381:Rats; D017382:Reactive Oxygen Species / Q000378:metabolism; D014158:Transcription, Genetic / Q000502:physiology
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D056572:Histone Deacetylase Inhibitors; D006657:Histones; D007527:Isoenzymes; D017382:Reactive Oxygen Species; D006655:Histone Deacetylases